Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Bryant Harbourne"'
Autor:
Nina E. Weisser, Mario Sanches, Eric Escobar-Cabrera, Jason O’Toole, Elizabeth Whalen, Peter W. Y. Chan, Grant Wickman, Libin Abraham, Kate Choi, Bryant Harbourne, Antonios Samiotakis, Andrea Hernández Rojas, Gesa Volkers, Jodi Wong, Claire E. Atkinson, Jason Baardsnes, Liam J. Worrall, Duncan Browman, Emma E. Smith, Priya Baichoo, Chi Wing Cheng, Joy Guedia, Sohyeong Kang, Abhishek Mukhopadhyay, Lisa Newhook, Anders Ohrn, Prajwal Raghunatha, Matteo Zago-Schmitt, Joseph D. Schrag, Joel Smith, Patricia Zwierzchowski, Joshua M. Scurll, Vincent Fung, Sonia Black, Natalie C. J. Strynadka, Michael R. Gold, Leonard G. Presta, Gordon Ng, Surjit Dixit
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-22 (2023)
The success of HER2-targeted cancer therapy is limited by treatment resistance. Here, the authors engineer an anti-HER2 biparatopic antibody with multiple mechanisms of action including induction of HER2 clustering to trigger complement dependent cyt
Externí odkaz:
https://doaj.org/article/8a871ad93e594eeba832492229b1329b
Autor:
Arun M Unni, Bryant Harbourne, Min Hee Oh, Sophia Wild, John R Ferrarone, William W Lockwood, Harold Varmus
Publikováno v:
eLife, Vol 7 (2018)
Synthetic lethality results when mutant KRAS and EGFR proteins are co-expressed in human lung adenocarcinoma (LUAD) cells, revealing the biological basis for mutual exclusivity of KRAS and EGFR mutations. We have now defined the biochemical events re
Externí odkaz:
https://doaj.org/article/c9a152b7e5fb4105b4de838a7f359c26
Autor:
Anna von Rossum, Genevieve Desjardins, Nichole Escalante, Wingkie Wong, Bryant Harbourne, Janessa Li, Begonia Silva Moreno, Prajwal Raghunatha, Richard Kunze, Madeline Fung, Florian Heinkel, Harsh Pratap, Kevin Haworth, Eric Escobar-Cabrera, Brandon Clavette, Surjit Dixit, Nina Weisser, Thomas Spreter von Kreudenstein
Publikováno v:
Cancer Research. 83:2926-2926
Many T-cell engagers (TCE) and immuno-oncology biologics have limited efficacy in the clinic due to narrow therapeutic windows, checkpoint upregulation, and emergence of resistance mechanisms over time. The PROTECTTM (PROgrammed Tumor Engagement & Ch